These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Under-use of secondary prevention medication in acute coronary syndrome patients treated with in-hospital coronary artery bypass graft surgery. Looi KL; Chow KL; Looi JL; Lee M; Halliday S; White H; Ellis C N Z Med J; 2011 Sep; 124(1343):18-27. PubMed ID: 21964009 [TBL] [Abstract][Full Text] [Related]
6. Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice. Kassab YW; Hassan Y; Aziz NA; Akram H; Ismail O J Eval Clin Pract; 2013 Aug; 19(4):658-63. PubMed ID: 22845427 [TBL] [Abstract][Full Text] [Related]
7. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. Vermeer NS; Bajorek BV J Clin Pharm Ther; 2008 Dec; 33(6):591-601. PubMed ID: 19138236 [TBL] [Abstract][Full Text] [Related]
8. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry. Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997 [TBL] [Abstract][Full Text] [Related]
9. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective. Griffiths B; Lesosky M; Ntsekhe M S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049 [TBL] [Abstract][Full Text] [Related]
10. Impact of a pharmacist-delivered discharge and follow-up intervention for patients with acute coronary syndromes in Qatar: a study protocol for a randomised controlled trial. Zidan A; Awaisu A; Kheir N; Mahfoud Z; Kaddoura R; AlYafei S; El Hajj MS BMJ Open; 2016 Nov; 6(11):e012141. PubMed ID: 27864247 [TBL] [Abstract][Full Text] [Related]
11. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome]. Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236 [No Abstract] [Full Text] [Related]
12. Use of evidence-based therapy for the prevention of cardiovascular events among older people. Castelino RL; Chen TF; Guddattu V; Bajorek BV Eval Health Prof; 2010 Sep; 33(3):276-301. PubMed ID: 20801973 [TBL] [Abstract][Full Text] [Related]
13. Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. Welker J; Auer R; Gencer B; Muller O; Cornuz J; Matter CM; Mach F; Windecker S; Rodondi N; Nanchen D Swiss Med Wkly; 2016; 146():w14275. PubMed ID: 26859223 [TBL] [Abstract][Full Text] [Related]
14. [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS]. Yahia DH; Pereg D; Lishner M; Elis A Harefuah; 2015 May; 154(5):299-302, 339-40. PubMed ID: 26168639 [TBL] [Abstract][Full Text] [Related]
15. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. Lee HY; Cooke CE; Robertson TA J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049 [TBL] [Abstract][Full Text] [Related]
16. Estimating mortality in survivors of the acute coronary syndrome by the 4-drug score. Kopel E; Klempfner R; Goldenberg I; Schwammenthal E Cardiology; 2014; 127(2):83-9. PubMed ID: 24280900 [TBL] [Abstract][Full Text] [Related]
17. In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea . Kang HB; Choi M; Yoon SG; Cho YS; Je NK Int J Clin Pharmacol Ther; 2018 Jan; 56(1):1-11. PubMed ID: 29168689 [TBL] [Abstract][Full Text] [Related]
18. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR). Zeymer U; Berkenboom G; Coufal Z; Belger M; Sartral M; Norrbacka K; Bakhai A; Int J Cardiol; 2013 Dec; 170(2):239-45. PubMed ID: 24225199 [TBL] [Abstract][Full Text] [Related]
19. Secondary prevention therapies for coronary heart disease in patients with type 2 diabetes: an audit. Sharma KK; Guptha S; Gupta R J Assoc Physicians India; 2012 Apr; 60():28-30. PubMed ID: 23029739 [TBL] [Abstract][Full Text] [Related]
20. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study. Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z; Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]